Stereotactic radiotherapy in the liver hilum

A basis for future trials with stereotactic body radiotherapy (SBRT) for tumors of the liver hilum should be established. Thus, dosage concepts, planning processes, and dose constraints as well as technical innovations are summarized in this contribution. On the background of our own data, the curre...

Full description

Saved in:
Bibliographic Details
Published in:Strahlentherapie und Onkologie 2012-01, Vol.188 (1), p.35
Main Authors: Zamboglou, C, Meßmer, M-b, Becker, G, Momm, F
Format: Article
Language:eng ; jpn
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c1422-40809bb8a142e947d99dbabb2539168cbc789c776fda914a51853a1ad4fb09123
cites
container_end_page
container_issue 1
container_start_page 35
container_title Strahlentherapie und Onkologie
container_volume 188
creator Zamboglou, C
Meßmer, M-b
Becker, G
Momm, F
description A basis for future trials with stereotactic body radiotherapy (SBRT) for tumors of the liver hilum should be established. Thus, dosage concepts, planning processes, and dose constraints as well as technical innovations are summarized in this contribution. On the background of our own data, the current literature was reviewed. The use of SBRT in the most common tumors of the liver hilum (pancreatic cancer and Klatskin tumors) was investigated. Dose constraints were calculated in 2 Gy standard fractionation doses. A total of 8 pilot or phase I/II studies about SBRT in the liver hilum were identified. In recent years, the SBRT technique has developed very quickly from classical stereotactic body frame radiotherapy to IGRT techniques including gating and tracking systems. In the studies using classical body frame technique, patients experienced considerable toxicities (duodenal ulcer/perforation) as compared to tolerable side effects in IGRT studies (
doi_str_mv 10.1007/s00066-011-0002-2
format article
fullrecord <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_journals_1021639162</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2693700091</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1422-40809bb8a142e947d99dbabb2539168cbc789c776fda914a51853a1ad4fb09123</originalsourceid><addsrcrecordid>eNotjc1KxDAURoMoWEcfwF3ArdF70zTJXcqgozDgQgV3Q_7KZKjTMW0F396Krr7zbc5h7BLhBgHM7QAAWgtAFDNJIY9YhaomAUTvx6wCNCQMNvaUnQ3DDgC1IlWx65cxldSPLow58OJi7sdtKu7wzfOez8i7_JUK3-Zu-jhnJ63rhnTxvwv29nD_unwU6-fV0_JuLQIqKYUCC-S9dfNLpEwkit55L5uaUNvgg7EUjNFtdITKNWib2qGLqvVAKOsFu_rzHkr_OaVh3Oz6qezn5AZBov7VyPoHnwlD0g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1021639162</pqid></control><display><type>article</type><title>Stereotactic radiotherapy in the liver hilum</title><source>Springer Nature</source><creator>Zamboglou, C ; Meßmer, M-b ; Becker, G ; Momm, F</creator><creatorcontrib>Zamboglou, C ; Meßmer, M-b ; Becker, G ; Momm, F</creatorcontrib><description>A basis for future trials with stereotactic body radiotherapy (SBRT) for tumors of the liver hilum should be established. Thus, dosage concepts, planning processes, and dose constraints as well as technical innovations are summarized in this contribution. On the background of our own data, the current literature was reviewed. The use of SBRT in the most common tumors of the liver hilum (pancreatic cancer and Klatskin tumors) was investigated. Dose constraints were calculated in 2 Gy standard fractionation doses. A total of 8 pilot or phase I/II studies about SBRT in the liver hilum were identified. In recent years, the SBRT technique has developed very quickly from classical stereotactic body frame radiotherapy to IGRT techniques including gating and tracking systems. In the studies using classical body frame technique, patients experienced considerable toxicities (duodenal ulcer/perforation) as compared to tolerable side effects in IGRT studies (&lt;10% grade 3 and 4 toxicities). Dose constraints for duodenum, liver, kidneys, colon, and spinal cord were derived from the investigated studies. Survival and local tumor control data are very heterogeneous: median survival in these patients with locally advanced pancreatic or Klatskin tumors ranges between 5 and 32 months. Excellent local tumor control rates of about 80% over 24 months were achieved using SBRT. Despite a few negative results, SBRT seems to be a promising technique in the treatment of tumors of the liver hilum. Highest precision in diagnostics, positioning, and irradiation as well as strict dose constraints should be applied to keep target volumes as small as possible and side effects tolerable.[PUBLICATION ABSTRACT]</description><identifier>ISSN: 0179-7158</identifier><identifier>EISSN: 1439-099X</identifier><identifier>DOI: 10.1007/s00066-011-0002-2</identifier><language>eng ; jpn</language><publisher>Heidelberg: Springer Nature B.V</publisher><ispartof>Strahlentherapie und Onkologie, 2012-01, Vol.188 (1), p.35</ispartof><rights>Urban &amp; Vogel 2012</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c1422-40809bb8a142e947d99dbabb2539168cbc789c776fda914a51853a1ad4fb09123</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids></links><search><creatorcontrib>Zamboglou, C</creatorcontrib><creatorcontrib>Meßmer, M-b</creatorcontrib><creatorcontrib>Becker, G</creatorcontrib><creatorcontrib>Momm, F</creatorcontrib><title>Stereotactic radiotherapy in the liver hilum</title><title>Strahlentherapie und Onkologie</title><description>A basis for future trials with stereotactic body radiotherapy (SBRT) for tumors of the liver hilum should be established. Thus, dosage concepts, planning processes, and dose constraints as well as technical innovations are summarized in this contribution. On the background of our own data, the current literature was reviewed. The use of SBRT in the most common tumors of the liver hilum (pancreatic cancer and Klatskin tumors) was investigated. Dose constraints were calculated in 2 Gy standard fractionation doses. A total of 8 pilot or phase I/II studies about SBRT in the liver hilum were identified. In recent years, the SBRT technique has developed very quickly from classical stereotactic body frame radiotherapy to IGRT techniques including gating and tracking systems. In the studies using classical body frame technique, patients experienced considerable toxicities (duodenal ulcer/perforation) as compared to tolerable side effects in IGRT studies (&lt;10% grade 3 and 4 toxicities). Dose constraints for duodenum, liver, kidneys, colon, and spinal cord were derived from the investigated studies. Survival and local tumor control data are very heterogeneous: median survival in these patients with locally advanced pancreatic or Klatskin tumors ranges between 5 and 32 months. Excellent local tumor control rates of about 80% over 24 months were achieved using SBRT. Despite a few negative results, SBRT seems to be a promising technique in the treatment of tumors of the liver hilum. Highest precision in diagnostics, positioning, and irradiation as well as strict dose constraints should be applied to keep target volumes as small as possible and side effects tolerable.[PUBLICATION ABSTRACT]</description><issn>0179-7158</issn><issn>1439-099X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><recordid>eNotjc1KxDAURoMoWEcfwF3ArdF70zTJXcqgozDgQgV3Q_7KZKjTMW0F396Krr7zbc5h7BLhBgHM7QAAWgtAFDNJIY9YhaomAUTvx6wCNCQMNvaUnQ3DDgC1IlWx65cxldSPLow58OJi7sdtKu7wzfOez8i7_JUK3-Zu-jhnJ63rhnTxvwv29nD_unwU6-fV0_JuLQIqKYUCC-S9dfNLpEwkit55L5uaUNvgg7EUjNFtdITKNWib2qGLqvVAKOsFu_rzHkr_OaVh3Oz6qezn5AZBov7VyPoHnwlD0g</recordid><startdate>20120101</startdate><enddate>20120101</enddate><creator>Zamboglou, C</creator><creator>Meßmer, M-b</creator><creator>Becker, G</creator><creator>Momm, F</creator><general>Springer Nature B.V</general><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FG</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20120101</creationdate><title>Stereotactic radiotherapy in the liver hilum</title><author>Zamboglou, C ; Meßmer, M-b ; Becker, G ; Momm, F</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1422-40809bb8a142e947d99dbabb2539168cbc789c776fda914a51853a1ad4fb09123</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng ; jpn</language><creationdate>2012</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zamboglou, C</creatorcontrib><creatorcontrib>Meßmer, M-b</creatorcontrib><creatorcontrib>Becker, G</creatorcontrib><creatorcontrib>Momm, F</creatorcontrib><collection>ProQuest Central (Corporate)</collection><collection>Proquest Nursing &amp; Allied Health Source</collection><collection>ProQuest Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>Advanced Technologies &amp; Aerospace Collection</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>Technology Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest Advanced Technologies &amp; Aerospace Database</collection><collection>ProQuest Advanced Technologies &amp; Aerospace Collection</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Strahlentherapie und Onkologie</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zamboglou, C</au><au>Meßmer, M-b</au><au>Becker, G</au><au>Momm, F</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Stereotactic radiotherapy in the liver hilum</atitle><jtitle>Strahlentherapie und Onkologie</jtitle><date>2012-01-01</date><risdate>2012</risdate><volume>188</volume><issue>1</issue><spage>35</spage><pages>35-</pages><issn>0179-7158</issn><eissn>1439-099X</eissn><abstract>A basis for future trials with stereotactic body radiotherapy (SBRT) for tumors of the liver hilum should be established. Thus, dosage concepts, planning processes, and dose constraints as well as technical innovations are summarized in this contribution. On the background of our own data, the current literature was reviewed. The use of SBRT in the most common tumors of the liver hilum (pancreatic cancer and Klatskin tumors) was investigated. Dose constraints were calculated in 2 Gy standard fractionation doses. A total of 8 pilot or phase I/II studies about SBRT in the liver hilum were identified. In recent years, the SBRT technique has developed very quickly from classical stereotactic body frame radiotherapy to IGRT techniques including gating and tracking systems. In the studies using classical body frame technique, patients experienced considerable toxicities (duodenal ulcer/perforation) as compared to tolerable side effects in IGRT studies (&lt;10% grade 3 and 4 toxicities). Dose constraints for duodenum, liver, kidneys, colon, and spinal cord were derived from the investigated studies. Survival and local tumor control data are very heterogeneous: median survival in these patients with locally advanced pancreatic or Klatskin tumors ranges between 5 and 32 months. Excellent local tumor control rates of about 80% over 24 months were achieved using SBRT. Despite a few negative results, SBRT seems to be a promising technique in the treatment of tumors of the liver hilum. Highest precision in diagnostics, positioning, and irradiation as well as strict dose constraints should be applied to keep target volumes as small as possible and side effects tolerable.[PUBLICATION ABSTRACT]</abstract><cop>Heidelberg</cop><pub>Springer Nature B.V</pub><doi>10.1007/s00066-011-0002-2</doi></addata></record>
fulltext fulltext
identifier ISSN: 0179-7158
ispartof Strahlentherapie und Onkologie, 2012-01, Vol.188 (1), p.35
issn 0179-7158
1439-099X
language eng ; jpn
recordid cdi_proquest_journals_1021639162
source Springer Nature
title Stereotactic radiotherapy in the liver hilum
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-10T23%3A53%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Stereotactic%20radiotherapy%20in%20the%20liver%20hilum&rft.jtitle=Strahlentherapie%20und%20Onkologie&rft.au=Zamboglou,%20C&rft.date=2012-01-01&rft.volume=188&rft.issue=1&rft.spage=35&rft.pages=35-&rft.issn=0179-7158&rft.eissn=1439-099X&rft_id=info:doi/10.1007/s00066-011-0002-2&rft_dat=%3Cproquest%3E2693700091%3C/proquest%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c1422-40809bb8a142e947d99dbabb2539168cbc789c776fda914a51853a1ad4fb09123%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1021639162&rft_id=info:pmid/&rfr_iscdi=true